Clinical Effectiveness of Sustained-Release Bupropion and Behavior Therapy for Tobacco Dependence in a Clinical Setting

Earles, Jay Edward; Folen, Raymond A.; Ma, Mindy; Kellar, Michael A.; Geralde, Renato; Dydek, George J.

doi:10.1093/milmed/167.11.923

Cited by 8 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The third report is from the Tripler Army Medical Center in USA involving primary care physicians and health psychologists (21). Smokers received bupropion SR for 10 weeks along with group cognitive‐behavioural therapy.…”

Section: Resultsmentioning

confidence: 99%

Bupropion as an aid to smoking cessation: a review of real-life effectiveness

Holmes¹,

Zwar

Jiménez-Ruíz

et al. 2004

International Journal of Clinical Practice

View full text Add to dashboard Cite

Clinical trials rigorously demonstrate the efficacy of new products and justify their marketing. However, it is only after use in real-life settings that the clinical value (effectiveness) of a new treatment is fully known. The purpose of this review was to summarise the effectiveness data for bupropion SR as an aid to smoking cessation. Available reports of effectiveness data for bupropion SR were obtained from the literature, presentations at smoking cessation meetings and from the manufacturer. Twelve sources of effectiveness data were found and included clinical practice trials, observational studies/surveys, motivational support programme results and employer-based cessation programme results. The 6-month point prevalence smoking cessation rates ranged from 25 to 49%. There is a growing body of evidence supporting the effectiveness of bupropion SR as an aid to smoking cessation. Real-life quit rates for bupropion SR are similar to those seen in the original clinical trial programme.

show abstract

Section: Resultsmentioning

confidence: 99%

Bupropion as an aid to smoking cessation: a review of real-life effectiveness

Holmes¹,

Zwar

Jiménez-Ruíz

et al. 2004

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…114 More men than women quit with combined cognitive/behavioral group therapy and sustained release bupropion. 115 Quitting smoking has been reported to be harder for women than men, partially because of concern of the perceived potential for weight gain if they quit. 112,113 Other reasons that women may have a more difficult time in quitting include NRTs (especially gum and patches) may not be as effective in women, the medications to aid smoking cessation are not recommended for pregnant women, the menstrual cycle affects tobacco withdrawal symptoms and response to antismoking drugs vary by cycle phase, husbands provide less effective support to women than women give to men, women may be more susceptible to environmental cues (such as friends and moods) associated with the smoking ritual, and some women may enjoy the feeling of control associated with smoking.…”

Section: Womenmentioning

confidence: 99%

Tobacco Cessation in Primary Care: Maximizing Intervention Strategies

Anczak¹,

Nogler²

2003

Clinical Medicine & Research

View full text Add to dashboard Cite

The most effective preventive intervention that a clinician can provide for tobacco-using patients against heart disease, cancer, cerebrovascular disease and chronic obstructive pulmonary disease is an empathic, personalized smoking cessation intervention program with extended assistance and follow-up. The goal of the intervention must be complete smoking cessation. Reduction provides no direct health benefits to the individual smoker. Interventions are readily available, but underutilized, in part due to lack of clinician training and organizational support.The present article summarizes the current guidelines for smoking cessation interventions as a framework from which to start. The guidelines incorporate the Transtheoretical Model of patient behavioral change and the "Five A's": Ask, Advise, Assess, Assist and Arrange. Pharmacotherapeutic tools, including nicotine replacement therapies (nicotine gums, patches, nasal sprays, inhalers and new therapies) and non-nicotine therapies (bupropion, clonidine, nortriptyline and other antidepressants and anxiolytics) are considered. Adherence validation methods, new approaches to tobacco and addiction treatment that appear in the recent research literature are reviewed.Beyond this framework, specific categories of tobacco users (including smokeless tobacco users), cultural and ethnic minorities, adolescents using snuff and bidis, women, Medicaid recipients, and users of multiple forms of tobacco require special consideration.With this framework and the modifications that may be required for specific categories of patients, practicing clinicians can incorporate into daily practice a successful tobacco cessation intervention program with quit rates approaching 20%.

show abstract

“…[100] Some studies, however, recommend NRT as the first line therapy for smoking cessation because of the amphetaminelike nature of bupropion, with some structural similarities, and similar side effects such as suppression of appetite, insomnia, weight loss and hypertension. [101] But several other studies claim that bupropion is a safe and efficacious drug [97,[102][103][104] and should be prescribed with consideration, especially to patients with hypertension. Study on selfadministered treatment for smoking cessation revealed that self-help manuals do increase quit rates when combined with individualised adjuncts such as written feedback and telephonic counselling.…”

Section: Resultsmentioning

confidence: 99%